Table 3-18 Autoimmune Antibodies |
| Antibody | | Antigen | | Prevalence | | Clinical Associations |
Systemic Lupus Erythematosus (SLE) |
| Anti-dsDNA | | Native DNA | | 40–90% | | Highly specific, lupus nephritis, correlates with disease activity, early/severe disease |
| Anti-Sm | | Ribonucleoprotein | | 10–30% | | Highly specific, lupus nephritis |
| Anti-rRNP | | Ribosomal P protein | | 10% | | Highly specific, neuropsychiatric LE |
| Anti-Ro (SSA) | | Ribonucleoprotein | | 40–60% | | Mild SLE, photosensitivity, SCLE, neonatal LE/congenital heart block |
| Anti-La (SSB) | | Ribonucleoprotein | | 20–30% | | Same as anti-Ro associations |
| Anti-U1RNP | | Ribonucleoprotein | | 30–60% | | SCLE, mild SLE with limited systemic involvement |
| Anti-histone | | Histone | | 40% | | Drug-induced
{SLE mainly but can also be seen in SCLE} |
| Anti-Ku | | p70/p80 nucleolar protein (DNA repair) | | 10% | | SLE with polymyositis |
| Anti-ssDNA | | Denatured DNA | | 70% | | Possible risk for SLE in DLE patients |
| Anti-C1q | | C1q of complement | | 60% | | Severe SLE, lupus nephritis |
| Anti-cardiolipin | | Cardiolipin (phospholipid) | | 50% | | |
Sjögren Syndrome |
| Anti-α-fodrin | | Actin-binding ptn | | 70% | | |
| Anti-Ro | | Ribonucleoprotein | | 60% | | ↑ Risk of systemic disease and lymphoma |
| Anti-La | | Ribonucleoprotein | | 35-85% | | Same as anti-Ro |
Systemic Sclerosis |
| Anti-Scl-70 | | DNA topoisomerase I | | 25% | | Diffuse skin disease, interstitial lung disease |
| Anti-RNA polymerase III | | RNA polymerase III | | 20% | | Rapid-onset and severe disease with major organ and diffuse cutaneous involvement |
| Anti-fibrillarin | | U3RNP | | | | Diffuse skin disease, pulmonary HTN |
| Anti-centromere | | 5–30% | | | | CREST |
| Anti-Ku | | p70/p80 nucleolar protein (DNA repair) | | 10% | | |
Dermatomyositis |
| Anti-155 kDa and anti-Se | | Uncharacterized nuclear proteins | | 80% | | Amyopathic dermatomyositis, cancer - associated dermatomyositis |
| Anti-Jo1 | | Histidyl tRNA synthetase | | 20% | | Antisynthetase syndrome: Raynaud’s phenomenon, mechanic’s hands, pulmonary fibrosis, arthritis, myositis |
| Anti-SRP | | Signal recognition particle | | 5% | | Cardiac involvement, severe DM/PM, poor prognosis |
| Anti-Mi2 | | Nuclear helicase | | 15% | | Hallmark skin lesions, good prognosis |
| Anti-Ku | | p70/p80 protein | | <5% | | DM/PM overlap with SLE or scleroderma |
| Anti-PM/Scl | | Nucleolar proteins | | <10% | | DM/PM overlapping with scleroderma |
| PL-7, PL-12 | | tRNA synthetase | | 3% | | Antisynthetase syndrome |
Mixed Connective Tissue Disease (MCTD) |
| Anti-U1RNP | | Ribonucleoprotein | | 100% | | |
| | | | | | | |